AstraZeneca shares rise

AstraZeneca shares rise as China probe update reassures
AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes for two cancer drugs, reassuring analysts and investors that the business impact would be minor.
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).
AstraZeneca sales jump despite troubles in China
UK drugmaker AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter of 2024. AstraZeneca ’s $14.
AstraZeneca shareholders say they need clarity on China investigations
AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one of its key markets.
AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
AstraZeneca CEO: UK must improve investment environment
Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...
Peer demands answers on AstraZeneca deal collapse
A Liberal Democrat peer has accused the government of favouring the south-east of England over Merseyside after AstraZeneca ...
AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
FierceBiotech17h
AstraZeneca CEO defends 'fantastic' Alexion buyout in face of $753M hit from dropped drug
Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...
AstraZeneca reports strong results boosted by promising trials
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...
AstraZeneca 'very disappointed' after scrapping £450m vaccine plant in Liverpool
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...
FiercePharma14h
AstraZeneca warns of potential tax fines amid China sales slowdown, illegal drug importation probe
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
GlobalData on MSN11h
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
Pharmaceutical giant AstraZeneca faces potential fines in China over import taxes
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
Here’s why AstraZeneca stock jumped nearly 6% in the FTSE 100 today
FTSE 100 heavyweight AstraZeneca helped propel the blue-chip index to a record high today. Here's what investors were ...
AstraZeneca Boss Says UK ‘Isn’t the Worst Place’ to Invest
The boss of AstraZeneca Plc said he does not believe the UK is the worst place to invest, striking a conciliatory tone just ...